Why Boston Scientific (BSX) Shares Are Trading Higher Today - Boston Scientific (NYSE:BSX)

Boston Scientific Corp BSX generated net sales of $3.24 billion in Q2 FY22, slightly beating the Wall Street estimate of $3.22 billion.
Sales increased 5.4% Y/Y on a reported basis, 9.6% on an operational basis, and 6.6% on an organic basis, better than the management estimate of approximately 3% - 6%.
The Company achieved an adjusted EPS of $0.44, beating the consensus of $0.42 and the guidance of $0.41 - $0.43.
Revenues from MedSurg increased 4.5% to $1.25 billion (4.8% organic), Cardiovascular segment generated $1.99 billion, +6% (7.8% organic).
The adjusted gross margin remained unchanged at almost 70%, with an adjusted operating income margin of 25%.
Outlook: Boston Scientific estimates net sales growth for Q3 of 6% - 8%, with adjusted EPS of $0.43 - $0.45, compared to the consensus of $0.45.
For FY22, the Company estimates sales growth of approximately 6.5% - 7.5%, versus the earlier range of 7%-9%.
BSX forecasts FY22 EPS of $1.74 - $1.77 (prior range of $1.74-$1.79) compared to the consensus of $1.76.
Price Action: BSX shares are up 7.27% at $40.72 during the market session on the last check Wednesday.

Boston Scientific Shares Are Flying Higher On Q2 Wall Street Beat, Upbeat Guidance